Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

CompletedOBSERVATIONAL
Enrollment

239

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Crohn's DiseaseIBD
Interventions
DRUG

Infliximab

No standard dosing regimen will be used and the dose will be determined by the treating physician

DRUG

Adalimumab

No standard dosing regimen will be used and the dose will be determined by the treating physician

Trial Locations (4)

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital, Cincinnati

53226

Medical College of Wisconsin, Milwaukee

06016

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

The Leona M. and Harry B. Helmsley Charitable Trust

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT04131504 - Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) | Biotech Hunter | Biotech Hunter